Wolverine Asset Management LLC Has $1.08 Million Position in Surmodics, Inc. (NASDAQ:SRDX)

Wolverine Asset Management LLC boosted its position in shares of Surmodics, Inc. (NASDAQ:SRDX) by 6.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 27,766 shares of the company’s stock after purchasing an additional 1,800 shares during the quarter. Wolverine Asset Management LLC’s holdings in Surmodics were worth $1,077,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC lifted its position in shares of Surmodics by 14.7% in the first quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock worth $151,000 after purchasing an additional 660 shares in the last quarter. Lazard Asset Management LLC increased its holdings in Surmodics by 13.4% during the first quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock worth $166,000 after buying an additional 673 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Surmodics by 7.5% in the first quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock valued at $202,000 after purchasing an additional 481 shares during the last quarter. Hardin Capital Partners LLC acquired a new position in shares of Surmodics in the second quarter valued at $206,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Surmodics in the second quarter valued at $229,000. Institutional investors own 96.63% of the company’s stock.

Surmodics Price Performance

SRDX stock opened at $38.56 on Wednesday. The stock has a market capitalization of $550.14 million, a PE ratio of -47.60 and a beta of 1.20. The company’s 50-day moving average is $38.54 and its 200-day moving average is $39.04. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.22. Surmodics, Inc. has a 1 year low of $25.17 and a 1 year high of $42.44.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.14. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.77%. The business had revenue of $33.23 million for the quarter, compared to analysts’ expectations of $30.69 million. Equities research analysts expect that Surmodics, Inc. will post 0.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on SRDX shares. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research note on Thursday, November 7th. StockNews.com initiated coverage on shares of Surmodics in a report on Thursday, November 7th. They set a “hold” rating for the company. Five research analysts have rated the stock with a hold rating, According to MarketBeat, Surmodics has an average rating of “Hold” and a consensus target price of $50.00.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).